Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Oxford BioTherapeutics Appoints Dr Eugen Leo

Published: Thursday, July 10, 2014
Last Updated: Thursday, July 10, 2014
Bookmark and Share
Dr. Leo will be responsible for driving the Company’s pipeline of ADCs into clinical development.

Oxford BioTherapeutics has announced the appointment of Eugen Leo, MD, PhD, MBA, as Head of Clinical Development. Dr. Leo brings substantial clinical development experience of targeted and first-in-class molecules, as well as extensive translational research experience, and will be responsible for driving the Company’s attractive pipeline of ADCs into clinical development.

Dr. Leo has more than 15 years of experience in phase I-III clinical development of targeted molecules including antibodies, antibody derivatives, kinase inhibitors, vaccines and antisense molecules. He previously worked at Micromet, where he held several positions with increasing seniority and was instrumental in developing the company’s BiTE (bi-specific T-cell engager) antibody platform to clinical proof-of-concept, which received “breakthrough therapy” designation by FDA on July 1, 2014.

Thereafter he held senior development positions at major pharmaceutical companies including Johnson & Johnson and Merck Serono, developing various first-in-class molecules in phase I and II.

Dr. Leo is a board-certified haematologist and medical oncologist, and is ESMO-certified. He studied medicine at the Universities of Freiburg, Aachen, Muenster, Zuerich (Switzerland) and Cincinnati (USA), and spent three years as a research fellow at the Sanford-Burnham Institute, La Jolla, CA (USA), working on signal transduction in cancer. He holds an Adjunct Professorship for Experimental Oncology at the Department of Hematology and Medical Oncology at Heidelberg University, Germany. He also obtained an MBA from Colorado State University.

“Recruiting someone of Eugen’s calibre is a key step for the company as we progress our pipeline of exciting ADC candidates into the clinic. With Eugen’s appointment, as well as the recent appointment of Dr. Keith Wilson as Chief Scientific Officer, we have an exceptionally strong team in place to accelerate the development of our novel antibody drug conjugate programs into their first clinical trials,” said Dr. Christian Rohlff, Oxford BioTherapeutics’ CEO.

Commenting on his appointment, Dr. Leo said: “Oxford BioTherapeutics has developed a highly attractive pipeline of novel antibody drug candidates that could advance cancer treatment substantially. This pipeline has been generated using the company’s very own proprietary target discovery platform, which provides access to a wealth of unique and selective cancer targets, and by accessing state-of-the-art ADC conjugate and toxin technologies. I am extremely glad to be able to work with the OBT team in bringing these highly promising cancer therapeutics into the clinic and to patients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oxford BioTherapeutics Takes Exclusive Rights to Use Xenomouse® Antibodies and ADC Technology
Company to develop novel antibody-drug conjugate for HER2-negative breast cancer.
Friday, May 16, 2014
OBT and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia
First clinical development candidate in $1 billion oncology investment alliance.
Thursday, January 02, 2014
OBT and Boehringer Ingelheim Enter Collaboration
Collaboration to discover novel antibody targets in cancer.
Monday, April 29, 2013
Menarini and OBT Sign Major Strategic Collaboration
Strategic alliance for the clinical development and manufacture of a portfolio of novel antibody-based cancer drugs.
Tuesday, October 30, 2012
Oxford BioTherapeutics Licenses Lonza’s GS Gene Expression System™
Agreement covers the research, development and commercial use of the GS System™ by Oxford BioTherapeutics.
Monday, September 05, 2011
Scientific News
Developing Novel Ear Infection Treatments
Research team engineers antibiotic gel for treating middle ear infections.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Wearable Microscope Can Measure Fluorescent Dyes Through Skin
UCLA research could make monitoring disease biomarkers easier and more cost-effective.
Potential of New Insect Control Traits in Agriculture
Researchers have discovered a protein that shows promise as an alternate corn rootworm control mechanism.
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Fighting Plant Pathogens with RNA
Researchers develop strategy that could lead to environmentally friendly fungicide to fight pathogens.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Gene Therapy Technique May Help Prevent Cancer Metastasis
Gene-regulating RNA molecules could help treat early-stage breast cancer tumors before they spread.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
Examining mtDNA May Help Identify Unknown Ancestry That Influences Breast Cancer Risk
Researchers studying mtDNA in a group of triple negative breast cancer patients found that 13 percent of participants were unaware of ancestry that could influence their risk of cancer.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!